Grant
Clinical Research Studies of Atirmociclib in HR+/HER2- and/or HER2+ Breast Cancer
Pfizer
- , Add deadline: choose a calendar
- Brazil, Mexico, Canada, Australia, France, Germany, Italy, Spain, United Kingdom, China, Japan, South Korea, Taiwan, United States
- Institution applies
- Oncology, Clinical Pharmacology and
About
Supports clinical studies of atirmociclib in breast cancer. Investigators can address recurrence after adjuvant CDK4/6 inhibition, combinations in hormone receptor-positive metastatic disease, or early clinical signals in HER2-positive disease.
Topics
- Atirmociclib, search World Wide
- Breast Cancer, search World Wide
- HR+/HER2, search World Wide
- HER2-positive disease, search World Wide
- CDK4/6 inhibition, search World Wide
- metastatic disease, search World Wide
- hormone receptor-positive, search World Wide
- recurrence, search World Wide
- clinical studies, search World Wide
Eligibility
Covers: Pfizer has allocated USD 8 million across up to six clinical studies lasting three years.
The geographic scope of the call is BR, MX, CA, AU, FR, DE, IT, ES, GB, CN, JP, KR, TW, US.
The institution and principal investigator must be based in one of the fourteen eligible countries. The principal investigator must be an employee or contractor of the requesting institution.
Source: cdn.pfizer.com